Department of Pathology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Clin Cancer Res. 2013 Jun 15;19(12):3121-9. doi: 10.1158/1078-0432.CCR-12-3077. Epub 2013 May 2.
microRNAs (miRNA) are posttranscriptional gene regulators that may be useful as diagnostic and/or prognostic biomarkers. We aim to study the expression profiles of a high number of miRNAs and their relationship with clinicopathologic and biologic relevant features in leukemic mantle cell lymphomas (MCL).
Expression profiling of 664 miRNAs was investigated using a high-throughput quantitative real-time PCR platform in 30 leukemic MCLs. Statistical and bioinformatic analyses were conducted to define miRNAs associated with different clinicopathologic parameters. Gene expression profiling was investigated by microarrays in 16 matching cases to study the potential genes and pathways targeted by selected miRNAs. The prognostic value of miR-34a was investigated in 2 independent series of 29 leukemic and 50 nodal MCLs.
Robust consensus clustering defined 2 main MCL subgroups with significant differences in the immunoglobulin (IGHV) mutational status, SOX11 expression, genomic complexity, and nodal clinical presentation. Supervised analyses of IGHV and SOX11 categories identified 17 and 22 miRNAs differentially expressed, respectively. Enriched targets of these miRNAs corresponded to relevant pathways in MCL pathogenesis such as DNA stress response, CD40 signaling, and chromatin modification. In addition, we found 7 miRNAs showing prognostic significance independently of IGHV status and SOX11 expression. Among them, miR-34a was also associated with poor prognosis in 2 independent series of leukemic and nodal MCL, and in cooperation with high expression of the MYC oncogene.
We have identified miRNAs and target pathways related to clinical and biologic variants of leukemic MCL, and validated miR-34a as a prognostic marker in MCL.
微小 RNA(miRNA)是转录后基因调控因子,可作为诊断和/或预后生物标志物。我们旨在研究大量 miRNA 的表达谱及其与白血病套细胞淋巴瘤(MCL)的临床病理和生物学相关特征的关系。
使用高通量实时定量 PCR 平台在 30 例白血病 MCL 中研究 664 种 miRNA 的表达谱。进行统计和生物信息学分析以定义与不同临床病理参数相关的 miRNA。通过 microarrays 研究 16 例匹配病例以研究选定 miRNA 靶向的潜在基因和途径。在 2 个独立的 29 例白血病和 50 例结外 MCL 系列中研究 miR-34a 的预后价值。
稳健的共识聚类定义了 2 个主要的 MCL 亚组,在免疫球蛋白(IGHV)突变状态、SOX11 表达、基因组复杂性和结外临床表现方面存在显著差异。对 IGHV 和 SOX11 类别的监督分析分别确定了 17 个和 22 个差异表达的 miRNA。这些 miRNA 的富集靶标对应于 MCL 发病机制中的相关途径,如 DNA 应激反应、CD40 信号转导和染色质修饰。此外,我们发现 7 个 miRNA 具有独立于 IGHV 状态和 SOX11 表达的预后意义。其中,miR-34a 在 2 个独立的白血病和结外 MCL 系列中也与预后不良相关,并且与 MYC 癌基因的高表达协同作用。
我们已经确定了与白血病 MCL 的临床和生物学变异相关的 miRNA 和靶途径,并验证了 miR-34a 作为 MCL 的预后标志物。